Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-09-30
2008-07-01
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S031000, C514S002600
Reexamination Certificate
active
07393837
ABSTRACT:
The present invention relates to a method of treating metabolic bone diseases in a patient, which comprises the modulation of PEX activity to modulate the bone micro-environmental concentrations of critical bone anabolic agents, namely PTH and PTHrP. The present invention also provides the use Of inhibitors of PEX activity, such as, the use of inhibitors of NEP and/or ECE and/or PEX such as phosphoramidon, and analogs thereof, to modulate and preferably increase PTH/PTHrP levels in bone microenvironment to consequently result in an increase in bone formation, as confirmed by serum bone markers, namely, osteocalcin, to thereby provide a novel method for treating metabolic bone diseases, such as osteomalacia, osteoporosis, osteopetrosis, Paget's disease and X-linked hypophosphatemic rickets.
REFERENCES:
patent: 6583114 (2003-06-01), Vickery
patent: 2264655 (1998-03-01), None
patent: WO-96/19246 (1996-06-01), None
patent: WO 97/37967 (1997-10-01), None
patent: WO-98/10078 (1998-03-01), None
patent: WO03/030956 (2003-04-01), None
2006 Chemical Abstracts Catalog, published 2006 by Chemical Abstracts Service, p. 52.
Dolan et al., “The Cost of Treating Osteoporitic Fractures in the United Kingdom Female Population” Osteoporosis Int. (1998) vol. 8, pp. 611-617.
Hassan et al. “Phosphoramidon, an Endotherlin Converting Enzyme Inhibitor Attenuates Local Gastric Ischemia-Reperfusion Injury in Rats” Life Sciences (1997) vol. 61, No. 10, pp. PL 141-147.
DuBois et al., “Role of abnormal neutral endopeptidase-like activities in HYP mouse bone cells in renal phosphate transport” American Journal of Physiology: Cell Physiology (2002) C1414-C1421.
Du, L. et al.,cDNA Cloning of the Murine Pex Gene Implicated in X-Linked Hypophosphatemia and Evidence for Expression in Bone, GENOMICS (1996) vol. 36, Article 0421, pp. 22-28, © Academic Press, Inc.
The HYP Consortium,A Gene(PEX)With Homologies to endopeptidases is Mutated in Patients With X-Linked Hypophosphatemic Rickets, Nature Genetics (1995), vol. 11 pp. 130-136, © The American Society for Clinical Investigation Inc.
Beck, Laurent et al.,Pex/PEX Tissue Distribution and Evidence for a Deletion in the 3′ Region of the Pex Gene in X-Linked Hypophosphatemic Mice, Journal of Clinical Investigation, (1997) vol. 99, No. 6, pp. 1200-1209.
Grieff, Marvin et al.,Expression and Cloning of the Human X-Linked Hypophosphatemia Gene cDNA, Biochemical and Biophysical Research Communications (1997), vol. 231, Article No. RC9976153, pp. 635-639., © Academic Press.
Guo, Rong et al.,Cloning and Sequencing of Human PEX from a Bone cDNA Library: Evidence for Its Developmental Stage-Specific Regulation in Osteoblasts, Journal of Bone and Mineral Research (1997), vol. 12, No. 7, pp. 1009-1017, © American Society for Bone and Mineral Research.
Lipman, Mark L. et al.,Cloning of Human PEX cDNA: Expression, Subcellular Localization, and Endopeptidase Activity, The Journal of Biological Chemistry (1998) vol. 273, No. 22, pp. 13729-13737, © The American Society for Biochemistry and Molecular Biology, Inc., Printed in U.S.A.
Schneider, Hans-Gerhard et al.,Parathyroid Hormone-Related Protein mRNA and Protein Expression in Multiple Myeloma : A Case Report, Journal of Bone and Mineral Research (1998), vol. 13, No. 10, pp. 1640-1643, © American Society for Bone and Mineral Research.
Guise, Theresa A. et al.Evidence for a Casual Role of Parathyroid Hormone-related Protein in the Pathogenisis of Human Breast Cancer-mediated Osteolysis, Journal of Clinical Investigation (1996), vol. 98, No. 7, pp. 1544-1549, © The American Society for Clinical Investigation, Inc.
Verma, Inder M. et al.,Gene Therapy—Promises, Problems and Prospects, Nature (1977), vol. 389, pp. 239-242, © Macmillan Publishers Ltd.
Anderson, W. French,Human Gene Therapy, Nature, vol. 392/Supp, pp. 25-30, © Macmillan Publishers Ltd.
Romano, Gaetano et al.,Latest Developments in Gene Transfer Technology: Achievements, Perspectives, and Controversies over Therapeutic Applications, Stem Cells 2000, vol. 18, pp. 19-39.
Keibzak, Gary M. et al.,Secondary Hyperparathyroidism in X-Linked Hypophosphatemic Mice, Endocrinology (1982), vol. 111, No. 2, pp. 650-652, © The Endocrine Society, Published in U.S.A.
Blydt-Hansen, Tom D. et al.,PHEX Expression in Parathyroid Gland and Parathyroid Hormone Dysregulation in X-Linked Hypophosphatemia, Pediatr. Nephrol. (1999), vol. 13, pp. 607-611. © IPNA.
Econs, Michael et al.,Positional Cloning of the PEX Gene: New Insights Into the Pathophysiology of X-Linked Hypophosphatemic Rickets, American Journal of Physiology—Renal Physiology (1997) vol. 42, pp. F489-F498.
Zmuda, Joseph M.,Recent Progress in Understanding the Genetic Susceptibility to Osteoporosis, Genetic Epidemiolgy (1999), vol. 16, pp. 356-367, © Wiley-Liss, Inc.
Friedman, E.A., Consequences and management of hyperphosphatemia in patients with renal insufficiency. Kidney Int Suppl. Jun. 2005;(95):S1-7. Review.
Goltzman David
Henderson Janet E.
Karaplis Andrew C.
Lipman Mark L.
Jiang Shaojia Anna
McGill University
Newton Trevor
Ogilvy Renault LLP
Olson Eric S
LandOfFree
Inhibition of PEX in the treatment of metabolic bone diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of PEX in the treatment of metabolic bone diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of PEX in the treatment of metabolic bone diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3969807